Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents

Pharmacotherapy

Volumn 36, Issue 7, 2016, Pages 781-796

  Fasinu, Pius S ^a   Phillips, Sarah ^a   ElSohly, Mahmoud A ^a,b   Walker, Larry A ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

cannabidiol; cannabis; drug development; medical marijuana; 9 tetrahydrocannabinol

Indexed keywords

CANNABIDIOL; CANNABINOID RECEPTOR; ENDOCANNABINOID; MEDICAL CANNABIS;

ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL PHARMACOLOGY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; EPILEPSY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; LENNOX GASTAUT SYNDROME; NEUROPROTECTION; PHYTOCHEMISTRY; REVIEW; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TOXICITY TESTING; TRANQUILIZING ACTIVITY; TREATMENT INDICATION; UNITED STATES;

EID: 84979657267     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1780     Document Type: Review

References (50)

1. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers 2007;4:1614–8.
2. Brill H. Marihuana: the first twelve thousand years. J Psychoactive Drugs 1981;13:397–8.
3. Machado Rocha FC, Stefano S, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care 2008;17:431–43.
4. Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012;2:241–54.
5. Radwan MM, Elsohly MA, Slade D, Ahmed SA, Khan IA, Ross SA. Biologically active cannabinoids from high-potency Cannabis sativa. J Nat Prod 2009;72:906–11.
6. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199–215.
7. Schultes RE, Klein WM, Plowman T, Lockwood TE. Cannabis: an example of taxonomic neglect. Botanical Museum Leaflets: Harvard University, 1974. 337–67.
8. Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis plant—do they exist? Br J Pharmacol 2010;160:523–9.
9. Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc 1940;62:196–200.
10. Mechoulam R, Shvo Y. Hashish-I: structure of cannabidiol. Tetrahedron 1963;19:2073–8.
11. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006;28:153–7.
12. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845–52.
13. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998;83:393–411.
14. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 2004;24:53–62.
15. Hermanson DJ, Marnett LJ. Cannabinoids, endocannabinoids and cancer. Cancer Metastasis Rev 2011;30:599–612.
16. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011;130:216–21.
17. Labrecque G, Hallé S, Berthiaume A, Morin G, Morin PJ. Potentiation of the epileptogenic effect of penicillin G by marihuana smoking. Can J Physiol Pharmacol 1978;56:87–96.
18. Hawksworth G, McArdle K. Metabolism and pharmacokinetics of cannabinoids. In: Guy GC, Robson PJ, Whittle BA. eds. The medicinal uses of cannabis and cannabinoids. London: London Pharmaceutical Press; 2004: 205–28.
19. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991;40:701–8.
20. Ohlsson A, Lindgren J, Andersson S, et al. Single dose kinetics of cannabidiol in man. In: Agurell S, Dewey WL, Willette RE, eds. The cannabinoids: chemical, pharmacologic, and therapeutic aspects. Orlando: Academic Press, 1984. 219–25.
21. Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet 2013;28:332–8.
22. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791–802.
23. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015;56:1246–51.
24. Martin RC, Faught E, Richman J, et al. Incidence and prevalence of epilepsy among older US Medicare beneficiaries. Neurology 2012;78:448–53.
25. Izquierdo I, Tannhauser M. Letter: the effect of cannabidiol on maximal electroshock seizures in rats. J Pharm Pharmacol 1973;25:916–7.
26. Szaflarski JP, Bebin EM. Cannabis, cannabidiol and epilepsy—from receptors to clinical response. Epilepsy Behav 2014;41:277–82.
27. Mechoulam R, Carlini E. Toward drugs derived from cannabis. Naturwissenschaften 1978;65:174–9.
28. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21:175–85.
29. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J 1986;69:14.
30. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana '90 International Conference on Cannabis and Cannabinoids. Kolympari, Crete, July 8–11, 1990.
31. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016;15:270–8.
32. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy (Dravet syndrome). In: Roger J, Bureau M, Dravet C, Dreifuss FE, Ferret A, Wolf P. eds. Epileptic syndromes in infancy, childhood and adolescence, 4th ed. London: John Libbey; 2005: 89–114.
33. Chiron C. Current therapeutic procedures in Dravet syndrome. Dev Med Child Neurol 2011;53:16–8.
34. Dulac O, N'guyen T. The Lennox-Gastaut syndrome. Epilepsia 1993;34:S7–17.
35. Ferrie CD, Patel A. Treatment of Lennox-Gastaut syndrome (LGS). Eur J Paediatr Neurol 2009;13:493–504.
36. Nabbout R, Chiron C. Stiripentol: an example of antiepileptic drug development in childhood epilepsies. Eur J Paediatr Neurol 2012;16:S13–7.
37. Noonan D. Marijuana's medical future. Sci Am 2015;312:32–4.
38. Volpe J. Hypoxic-ischemic encephalopathy: neuropathology and pathogenesis. Neurol Newborn 2001;4:296–330.
39. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008;192:306–7.
40. Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry 2010;197:285–90.
41. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94.
42. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995;56:485–6.
43. Zuardi AW, Hallak JE, Dursun SM, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006;20:683–6.
44. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 2009;23:979–83.
45. Almeida V, Levin R, Peres FF, et al. Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test. Prog Neuropsychopharmacol Biol Psychiatry 2013;41:30–5.
46. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment naive social phobia patients. Neuropsychopharmacology 2011;36:1219–26.
47. Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 2014;71:281–91.
48. Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD Oromucosal Spray, Sativex) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014;71:173–81.
49. Reily RJ, Ferner M. House Blocks DEA from Targeting Medical Marijuana. Huffington Post. May 30, 2014. Available from http://www.huffingtonpost.com/2014/05/30/dea-medical-marijuana-house-vote_n_5414679.html. Accessed June 8, 2016.
50. Nickles DM. Federalism and state marijuana legislation. Notre Dame L Rev 2015;91:1253.